Structural And Functional Studies Of The Human IL-3 Receptor
Funder
National Health and Medical Research Council
Funding Amount
$307,946.00
Summary
This proposal will study a protein hormone that is implicated in blood cell cancers and inflammatory diseases and for which current treatments are inadequate. We will determine how the hormone receptor becomes activated, identify and characterise new agents that block this activation. This information will help in the development of new and highly specific drugs for use in certain cancers in inflammatory diseases.
TOLL LIKE RECEPTORS AGGRAVATE GLOMERULONEPHRITIS AND KIDNEY INJURY IN RENAL VASCULITIS
Funder
National Health and Medical Research Council
Funding Amount
$110,068.00
Summary
Anti neutrophil cytoplasmic antibody associated vasculitis (AAV) is a significant cause of morbidity and mortality. My thesis will explore the role of Toll Like Receptor (TLR) 2 and TLR9 in the initiation and pathogenesis of AAV and the therapeutic potential of TLR2/9 inhibitors. I will use both a murine experimental model and human kidney biopsy samples in this work. My thesis will further define the critical molecular events that underlie the disease whilst addressing potential new therapies.
Inflammasome Function In Protection Against Infectious Disease And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Inflammation, characterised by swelling, heat, pain and redness, is a normal response to injury and infection. Many human diseases such as gout, athersclerosis, diabetes and Alzheimer’s disease involve some inflammation, mediated through a common pathway termed the inflammasome. This project will investigate the proteins involved in this pathway and how they interact in their normal role of combatting infections, as well as a possible defect in this pathway in autoimmune patients.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes, Alzheimer’s and Parkinson's. This research program will reveal how the body deactivates inflammasomes – protein complexes at the heart of inflammation and disease – so we can design better drugs for treating patients with inflammation-driven disease.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes and Alzheimer’s. This project will reveal how the body deactivates inflammasomes - protein complexes at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation-driven disease.
The Regulatory Role Of Clec12A In Antigen Presentation And Inflammatory Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,381,077.00
Summary
The immune system maintains a balance between initiating immune responses to infections and suppressing immune responses in health. We have identified, on the surface of specialised immune cells, a protein that is critical for regulating immune responses and dampening down inflammation. This proposal aims to determine how this protein functions in health and under inflammatory conditions, and to develop approaches based on its molecular interactions to reduce inflammatory disease.
Role For Dipeptidyl Peptidase-IV In The Innate Immune Response
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
The innate immune system is the bodyÍs first line of defence in fighting off infections by invading organisms. An inappropriate innate immune response can lead to the development of several inflammatory conditions such as inflammatory bowel disease. A malfunctioning innate immune response has been identified in children with IBD. This project will determine the role of a unique enzyme called DPIV in the development of innate immune responses and its potential as a therapeutic target for IBD.
The Role Of BAFF, Its Receptor TACI And Toll-like Receptors In Autoimmunity And Tolerance.
Funder
National Health and Medical Research Council
Funding Amount
$486,824.00
Summary
There are 2 types of immune cells, innate cells reacting broadly against microbial elements, and adaptive cells educated to remember pathogens and provide improved immune responses. Most treatments against lupus target the adaptive cells with mixed success. We have discovered a new mechanism driving lupus at the level of innate immunity. This proposal will identify molecular players driving this unappreciated form of lupus and validate new therapeutic targets.
Structural And Functional Investigation Of Killer-Cell Immunoglobulin-like Receptors
Funder
National Health and Medical Research Council
Funding Amount
$546,966.00
Summary
Natural Killer (NK) cells are an important component of the immune response to cancer and infection. This project will define the molecular targets that are recognised by NK cells. This knowledge can then be used as a guide in the selection of bone marrow donors in the treatment of leukaemias as well as understanding how we fight infections.
Understanding Natural Killer Cell Development And Target Recognition
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Immune detection and eradication or control of cancer and cancer immunotherapies are based in part on the idea that tumour-specific white blood cells can protect the body from tumour development, growth and metastases. While strong evidence supports this, the means by which these white cells first recognize the cancerous tissue is largely unknown. We will study a new family of white blood cell receptors that may be important in this recognition, either naturally or following therapy.